| Project/Area Number |
19K21340
|
|---|
| Project/Area Number (Other) |
18H06244 (2018)
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund (2019)
Single-year Grants (2018) |
|---|
| Review Section |
0905:Surgery of the organs maintaining homeostasis and related fields
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-08-24 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 大動脈瘤 / マクロファージ / Focal Adhesion Kinase / FAK / focal adhesion kinase |
|---|
| Outline of Research at the Start |
マクロファージ特異的なFAK阻害療法を開発し、その効果を培養マクロファージで確認する。さらにそのFAK阻害療法の有効性をマウス大動脈瘤モデルにおいて検証する。
|
| Outline of Final Research Achievements |
The aim of this study was to develop an antibody therapeutic that has a beneficial effect specifically on macrophages, in order for pharmacotherapy of aortic aneurysm to be realized. Murine bone marrow-derived macrophages up-regulated NALP3 expression in response to LPS stimulation. We found that the LPS-induced increase in NALP3 was effectively suppressed by the delivery of anti-NALP3 antibody into the macrophages. Our data suggest a new concept for controlling inflammation by antibody therapeutics specific to macrophages.
|
| Academic Significance and Societal Importance of the Research Achievements |
大動脈瘤は破裂による突然死を来たし、高齢者男性死因の上位を占める疾患である。大動脈瘤の治療法は外科的治療に限られているため、全身副作用の無い安全な薬物療法の開発が待ち望まれている。本研究の成果が、大動脈瘤に対する抗体製剤の開発と実用化に繋がれば、多くの大動脈瘤患者が無侵襲に治療可能となり、患者予後の改善が期待される。また、大動脈瘤のみならず広く慢性炎症性疾患に対して、新たな作用機序の抗炎症薬の提供に繋がる。
|
